Newsroom
Sorted by: Latest
-
ライフゾーン・メタルズ、カバンガ・ニッケル・プロジェクトを巡るOrion CMCとの交渉がかなり進展していることを確認
ニューヨーク--(BUSINESS WIRE)--(ビジネスワイヤ) -- ライフゾーン・メタルズ・リミテッド(NYSE:LZM)は、オリオン・リソース・パートナーズの創業者兼グループ最高経営責任者であるOskar Lewnowski氏が、タンザニアにおけるライフゾーン・メタルズの「カバンガ・ニッケル・プロジェクト」に関してブルームバーグテレビジョンのインタビューで述べた内容についてお知らせします。 インタビュー後にメディアや投資家から寄せられた問い合わせを受け、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの大規模な出資を巡るオリオン重要鉱物コンソーシアム(Orion CMC)との交渉がかなり進展していることを確認しました。 Orion CMCは、オリオン・リソース・パートナーズが米国国際開発金融公社(DFC)およびアブダビの政府系投資会社ADQと提携して立ち上げたグローバル投資プラットフォームです。 既に発表しているとおり、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの戦略的投資を確保するため、スタンダードチャータード銀行が主導する競争的プロセスを進...
-
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with...
-
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph....
-
Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details
TORONTO--(BUSINESS WIRE)--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the “Interim Order”) of the Ontario Superior Court of Justice (Commercial List) (the “Court”) in connection with the proposed acquisition by EP/BRX Holdings LLC (the “Purchaser”), a joint venture between an affiliate of Brixmor Property Group Inc. and affiliates of Everview Partners, L.P., of all...
-
Deux machines haut de gamme de découpe laser de tubes font leurs débuts en Europe : Bodor Laser présente des solutions complètes de fabrication métallique à l’EuroBLECH 2026
HANOVRE, Allemagne--(BUSINESS WIRE)--Bodor Laser présentera deux nouvelles machines haut de gamme de découpe laser de tubes à l’EuroBLECH 2026, qui feront leurs débuts européens lors du plus grand salon mondial dédié à l’usinage de la tôle. L’événement se tiendra du 20 au 23 octobre à Hanovre. Bodor Laser sera présent dans le hall 13, aux stands A181 et A182, sur une surface d’exposition de plus de 1 400 m². Ces deux nouvelles machines offrent des solutions distinctes pour améliorer la producti...
-
Due macchine laser premium per il taglio di tubi fanno il loro debutto in Europa con la presentazione da parte di Bodor Laser di soluzioni complete per la lavorazione dei metalli a EuroBLECH 2026
HANNOVER, Germania--(BUSINESS WIRE)--Bodor Laser presenterà per la prima volta in Europa due nuove macchine laser premium per il taglio di tubi a EuroBLECH 2026, la fiera commerciale leader al mondo per la lavorazione della lamiera. L'evento si terrà dal 20 al 23 ottobre ad Hannover, e Bodor Laser sarà presente nella Hall 13, stand A181 e A182, su una superficie espositiva di oltre 1.400 m². Le due nuove macchine offrono percorsi distinti in direzione di una produttività superiore per la lavora...
-
Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
KENNETT SQUARE, Pa.--(BUSINESS WIRE)--Genesis Healthcare, Inc. (“Genesis”) today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W. State Street, LLC (“West State Street”) on October 14, 2026.On behalf of the Board of Directors, the Company thanks its management team, its employees and staff for their focus and dedication throughout the chapter 11 process. Despite a long and complex case, the Company’s fin...
-
Rosen Law Firm Encourages NVE Corporation Investors to Inquire About Securities Class Action Investigation - NVEC
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of NVE Corporation (NASDAQ: NVEC) resulting from allegations that NVE Corporation may have issued materially misleading business information to the investing public. So What: If you purchased NVE Corporation securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee...
-
US Metro Bancorp Announces Third Quarter 2026 Results
GARDEN GROVE, Calif.--(BUSINESS WIRE)--US Metro Bancorp (OTCQX: USMT): US Metro Bancorp (“Bancorp”) is a bank holding company, with a single subsidiary, US Metro Bank (“Bank”). On a consolidated basis, Bancorp earned $3.1 million in the third quarter of 2026, compared to $3.5 million in the second quarter of 2026. For the nine months ending September 30, 2026, the consolidated Bancorp earned $9.9 million compared to $8.0 million for the nine months ending September 30, 2025. On a year-to-date b...
-
BeOne Medicines、HER2陽性胃食道がんの一次治療における「TEVIMBRA」と「ZIIHERA」の併用による生存期間延長効果の持続を報告
カリフォルニア州サンカルロス--(BUSINESS WIRE)--(ビジネスワイヤ) -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.(Nasdaq:ONC、HKEX:06160、SSE:688235)は、第3相HERIZON-GEA-01試験の事前に計画された第2回中間解析(IA2)および正式な最終解析から得られた生存期間に関する新たな結果を発表しました。これらの結果は、HER2陽性の局所進行性または転移性胃食道腺がん(GEA)患者の一次治療として、TEVIMBRA®(チスレリズマブ)、ZIIHERA®(ザニダタマブ)および化学療法の併用療法の有効性をさらに裏付けるものです。この結果は、スペインのマドリードで開催される「欧州臨床腫瘍学会(ESMO)2026年大会」のラピッド・オーラル・セッションで、レイト・ブレイキング演題として発表されます(LBA79)。 BeOneの固形腫瘍部門最高医学責任者であるマーク・ラナサ医学博士・哲学博士は、次のように述べました。 「8月の米国での承認に続き、今回の長期追跡データは、PD-L1の発現状態にかかわらず、HER...